Physician profile
Eric C Fee
NPI 1255322178
$9,220.77
in general payments reported to CMS, 2019-2025
45 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $1,354 · 2021: $1,027 · 2022: $1,362 · 2023: $1,475 · 2024: $1,273 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,805.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,353.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,029.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $984.78 | 2021-2025 | |
| Pfizer INC. | $814.12 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $508.79 | 2019-2020 | |
| Lilly USA, LLC | $468.57 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $377.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $349.64 | 2019-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.68 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $305.97 | 2022-2025 | |
| Amarin Pharma, INC. | $296.23 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.67 | 2019-2022 | |
| Astellas Pharma US INC | $260.29 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $217.17 | 2022 | |
| Allergan, INC. | $180.29 | 2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Fee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.